Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm notes Sage reported the Phase 2 LIGHTWAVE study of dalzanemdor in mild AD/MCI failed to demonstrate a statistical significance improvement from baseline on the primary endpoint of change in WAIS-IV score. Wedbush acknowledges that this was not an opportunity it previously incorporated in its estimates so nothing to remove. Sage will discontinue further efforts for dalzanemdor in AD but continues to anticipate DIMENSION data in Huntington’s disease in Q4 2024. Given the prior failures observed with dalzanemdor to date, the firm remains cautious on the potential for the Huntington’s readout to show meaningful effects.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $6 from $11 at BofA
- Sage Therapeutics price target lowered to $9 from $13 at Baird
- Sage study failure removes another potential upside driver, says Stifel
- Sage Therapeutics falls 21% after Phase 2 dalzanemdor results miss endpoint
- Sage Therapeutics’ dalzanemdor did not meet primary endpoint in Phase 2 study